A carregar...
The use of tafasitamab in diffuse large B-cell lymphoma
Patients who relapse or are refractory after first-line therapy for diffuse large B-cell lymphoma (DLBCL) frequently have poor prognoses, especially when they are not candidates for autologous stem cell transplant (ASCT). Tafasitamab is a humanized monoclonal anti-CD19 antibody that has recently bee...
Na minha lista:
| Publicado no: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8264734/ https://ncbi.nlm.nih.gov/pubmed/34285786 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20406207211027458 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|